TransCode Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell RNAZ and other ETFs, options, and stocks.About RNAZ
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
CEOPhilippe P. Calais
CEOPhilippe P. Calais
Employees7
Employees7
HeadquartersBoston, Massachusetts
HeadquartersBoston, Massachusetts
Founded2016
Founded2016
Employees7
Employees7
RNAZ Key Statistics
Market cap6.79M
Market cap6.79M
Price-Earnings ratio-0.03
Price-Earnings ratio-0.03
Dividend yield—
Dividend yield—
Average volume39.13K
Average volume39.13K
High today$7.40
High today$7.40
Low today$6.57
Low today$6.57
Open price$6.71
Open price$6.71
Volume20.23K
Volume20.23K
52 Week high$468.44
52 Week high$468.44
52 Week low$6.08
52 Week low$6.08
Stock Snapshot
As of today, TransCode Therapeutics(RNAZ) shares are valued at $7.40. The company's market cap stands at 6.79M, with a P/E ratio of -0.03.
On 2026-01-03, TransCode Therapeutics(RNAZ) stock moved within a range of $6.57 to $7.40. With shares now at $7.40, the stock is trading +12.6% above its intraday low and 0.0% below the session's peak.
Trading activity shows a volume of 20.23K, compared to an average daily volume of 39.13K.
The stock's 52-week range extends from a low of $6.08 to a high of $468.44.
The stock's 52-week range extends from a low of $6.08 to a high of $468.44.
People also own
Based on the portfolios of people who own RNAZ. This list is generated using Robinhood data, and it’s not a recommendation.